Abacavir/lamivudine

Drug Profile

Abacavir/lamivudine

Alternative Names: Epivir/ziagen; EPZICOM; Kivexa; lamivudine/abacavir; Ziagen/Epivir

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline; ViiV Healthcare
  • Developer GlaxoSmithKline; Mylan
  • Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 05 Aug 2011 ViiV healthcare files lawsuit against Teva Pharmaceutical for infringing patent US 6 417 191
  • 01 Jul 2010 GlaxoSmithKline completes a phase III trial (NCT00440947, ARIES) of a regimen of atazanavir + ritonavir in combination with abacavir/lamivudine in treatment-naive patients with HIV-1 infection in USA, Canada, and Puerto Rico
  • 24 Feb 2010 Final efficacy and adverse events data from a phase III trial (ACTG 5202) in HIV infections presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top